Cargando…

Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges

SIMPLE SUMMARY: Efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration....

Descripción completa

Detalles Bibliográficos
Autores principales: Helderman, Roxan F. C. P. A., Löke, Daan R., Tanis, Pieter J., Tuynman, Jurriaan B., Ceelen, Wim, de Hingh, Ignace H., van der Speeten, Kurt, Franken, Nicolaas A. P., Oei, Arlene L., Kok, H. Petra, Crezee, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303745/
https://www.ncbi.nlm.nih.gov/pubmed/34298644
http://dx.doi.org/10.3390/cancers13143430
_version_ 1783727162308689920
author Helderman, Roxan F. C. P. A.
Löke, Daan R.
Tanis, Pieter J.
Tuynman, Jurriaan B.
Ceelen, Wim
de Hingh, Ignace H.
van der Speeten, Kurt
Franken, Nicolaas A. P.
Oei, Arlene L.
Kok, H. Petra
Crezee, Johannes
author_facet Helderman, Roxan F. C. P. A.
Löke, Daan R.
Tanis, Pieter J.
Tuynman, Jurriaan B.
Ceelen, Wim
de Hingh, Ignace H.
van der Speeten, Kurt
Franken, Nicolaas A. P.
Oei, Arlene L.
Kok, H. Petra
Crezee, Johannes
author_sort Helderman, Roxan F. C. P. A.
collection PubMed
description SIMPLE SUMMARY: Efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assists in designing potentially more effective treatment protocols and clinical trials. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In total, 60 articles were included in this study. The selected articles were screened on the HIPEC parameters. Recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments. ABSTRACT: Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritoneal metastasis (PM) of various origins which aims for cure in combination with cytoreductive surgery (CRS). Efficacy of CRS-HIPEC depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assist in designing potentially more effective treatment protocols and clinical trials. The different methodologies for peritoneal disease and HIPEC are variable. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In this review, recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments.
format Online
Article
Text
id pubmed-8303745
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83037452021-07-25 Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges Helderman, Roxan F. C. P. A. Löke, Daan R. Tanis, Pieter J. Tuynman, Jurriaan B. Ceelen, Wim de Hingh, Ignace H. van der Speeten, Kurt Franken, Nicolaas A. P. Oei, Arlene L. Kok, H. Petra Crezee, Johannes Cancers (Basel) Review SIMPLE SUMMARY: Efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assists in designing potentially more effective treatment protocols and clinical trials. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In total, 60 articles were included in this study. The selected articles were screened on the HIPEC parameters. Recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments. ABSTRACT: Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritoneal metastasis (PM) of various origins which aims for cure in combination with cytoreductive surgery (CRS). Efficacy of CRS-HIPEC depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assist in designing potentially more effective treatment protocols and clinical trials. The different methodologies for peritoneal disease and HIPEC are variable. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In this review, recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments. MDPI 2021-07-08 /pmc/articles/PMC8303745/ /pubmed/34298644 http://dx.doi.org/10.3390/cancers13143430 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Helderman, Roxan F. C. P. A.
Löke, Daan R.
Tanis, Pieter J.
Tuynman, Jurriaan B.
Ceelen, Wim
de Hingh, Ignace H.
van der Speeten, Kurt
Franken, Nicolaas A. P.
Oei, Arlene L.
Kok, H. Petra
Crezee, Johannes
Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges
title Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges
title_full Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges
title_fullStr Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges
title_full_unstemmed Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges
title_short Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges
title_sort preclinical in vivo-models to investigate hipec; current methodologies and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303745/
https://www.ncbi.nlm.nih.gov/pubmed/34298644
http://dx.doi.org/10.3390/cancers13143430
work_keys_str_mv AT heldermanroxanfcpa preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges
AT lokedaanr preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges
AT tanispieterj preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges
AT tuynmanjurriaanb preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges
AT ceelenwim preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges
AT dehinghignaceh preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges
AT vanderspeetenkurt preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges
AT frankennicolaasap preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges
AT oeiarlenel preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges
AT kokhpetra preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges
AT crezeejohannes preclinicalinvivomodelstoinvestigatehipeccurrentmethodologiesandchallenges